Key Takeaways Face/neck: NB-UVB or excimer + tacrolimus 0.1% is first-line; consider label-eligible topical JAK for added speed in limited […]
Key Takeaways Stability first: no new/enlarging macules for ≥6–12 months, quiet Wood’s-lamp rim, and no Koebner activity. Best sites: face/neck
Key Takeaways Vitiligo shows chalk-/blue-white accentuation on Wood’s lamp with sharp borders and possible perifollicular islands. Scale, itch, or coppery/yellow
Key Takeaways Most actionable comorbidity: autoimmune thyroid disease (subclinical → overt). Start with TSH, reflex to FT4 if abnormal; add
Key Takeaways Relapse is driven by tissue-resident memory T cells (TRM) and the IFN-γ–CXCL9/10 chemokine loop that re-recruits cytotoxic T
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Key Takeaways Segmental vitiligo (SV): unilateral/dermatomal clusters, rapid early spread then stability, frequent leukotrichia, limited systemic autoimmunity, best long-term results
Key Takeaways Wood’s lamp (365 nm) accentuates depigmented macules as bright blue-white/chalk-white with sharp rims. Dermoscopy helps confirm perifollicular islands, border
Key Takeaways Highest efficacy on face/neck with early perifollicular islands; moderate on trunk/limbs; limited on acral sites without phototherapy add-ons.
